The National Drug Alliance Procurement Office has issued a notification to suspend the manufacturing and marketing of piracetam by Zhuhai Hefan Medicine Co., Ltd. The suspension comes as a result of severe defects found in the company’s manufacturing management process, which are in direct violation of the Good Manufacturing Practice (GMP) standards.
Impact on Hefan Medicine’s Piracetam in Volume-Based Procurement (VBP)
Piracetam, which was a winning bid in the ninth volume-based procurement (VBP) round, will now see Hefan Medicine stripped of its winning status. The company is also banned from filing for VBP from November 29, 2024, to May 28, 2026. This measure is taken to ensure that all products meeting the standards of quality and safety are procured through the VBP process.-Fineline Info & Tech
Leave a Reply